NFKB1 and neoplasm: Considering that RCC is a tumor type that is strongly influenced by immunomodulatory and inflammation processes, it was previously shown that targeting the NF‐κB pathway blocks RCC tumor growth in vivo [23, 24, 25, 26, 27, 28].